Alvarez-Larrán et al.
1 in their reply letter state that Polycythaemia Vera Study Group criteria are currently used for the diagnosis of chronic myeloproliferative disorders and quote two important publications. Both these publications are recent; however, Carobbio et al. Alvarez-Larrán et al. are somewhat inconsistent using WHO criteria for diagnosis of primary myelofibrosis in their study but not for essential thrombocythaemia. The fibrosis grading system in their publication 5 does not include collagen deposition and is divergent with the current grading system.
6
It is interesting to learn that with substantial follow-up (10 years) that myelofibrosis did not develop despite moderate fibrosis in these 20 essential thrombocythaemia patients. There is no doubt that there is considerable difficulty in distinguishing essential thrombocythaemia from early-phase chronic idiopathic myelofibrosis/primary myelofibrosis. For the time being we will have to accept a disagreement in utilization of classification systems. The Polycythaemia Vera Study Group (PVSG) criteria 1 are used for the diagnosis of essential thrombocythaemia and polycythemia vera by many clinicians and researchers. On the contrary, since the PVSG did not establish specific criteria for the diagnosis of primary myelofibrosis, the criteria of the Italian Consensus Conference or the WHO criteria are the options currently employed to diagnose this disease. Consequently, there is no inconsistency in using the PVSG criteria for essential thrombocythaemia diagnosis and the WHO criteria for primary myelofibrosis.
2 With regard to the fibrosis scoring system, collagen deposition was assessed in all marrow biopsies, with none of our essential thrombocythaemia patients showing collagen fibrosis at essential thrombocythaemia presentation, as established in the PVSG criteria. Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder that is characterized by leukocytosis, thrombocytosis and anemia with myeloid hyperplasia in the bone marrow. 1 It affects 4500 people in the United States each year. Leukocytosis is invariably present with varying numbers of immature myeloid cells in the blood. Usually o5% circulating blasts are noted. Generally, there is a sustained and progressive rise in the white count; however, in a few instances there may be a periodic oscillation in peripheral blood leukocytes with or without antileukemic therapy.
2 The platelet count is typically high or normal, but on occasion severe thrombocytopenia may be seen.
3 Most patients are anemic and on occasion require red blood cell transfusion. The gold standard for diagnosis of CML is detection of the Philadelphia chromosome (t(9;22) (q34.1;q11.21)) and/or the Bcr-Abl1 hybrid gene.
We report a case of a 43-year-old male with a clinical picture resembling a myelodysplastic syndrome who presented with severe thrombocytopenia, mild anemia, normal WBC, splenomegaly and only erythroid hyperplasia in the bone marrow. Surprisingly, he was found to have t(9;22) on cytogenetic analysis. This patient was treated with imatinib mesylate and responded well. All blood counts returned to normal with disappearance of the cytogenetic abnormality. This response has persisted for more than 6 years. To the best of our knowledge, this presentation and response has not been described previously.
A 43-year-old man with no significant past medical history, presented on July 13, 2001 with a 10-day history of fatigue and easy bruising. He also described a recent weight loss of 10-15 lb. He denied fever, chills, night sweats or recurrent infections. He denied occupational exposure to toxic fumes or solvents. His family history was significant for lung cancer in his father and breast cancer in his mother. On physical examination, he appeared healthy but anxious. He was mildly icteric. There was no peripheral lymphadenopathy. Abdominal examination revealed 4 cm splenomegaly with no tenderness. Skin examination revealed mild ecchymoses. Rectal exam was unremarkable and stools were negative by Hemoccult testing.
On presentation his white blood cell count was 5.6 Â 10 9 l À1 with 38% segs, 19% bands, 3% lymphocytes, 5% monocytes, 3% metamyelocytes, 3% myelocytes, 1% blasts and 36% nucleated red cells. Hemoglobin was 10.3 g dl À1 with a striking mean corpuscular volume of 118 and platelets were 16 Â 10 9 l
À1
. Lactate dehydrogenase was normal at 179. Coombs testing was negative. A liver panel was normal except for a bilirubin of 1.6, which was mostly indirect. Renal function was normal. Human immunodeficiency virus 1 and 2 were negative. An serum protein electrophoresis (SPEP) was normal. Urine protein electrophoresis was negative. Antinuclear antibodies (ANA) as well as testing for cytomegalovirus, toxoplasmosis and viral hepatitis were negative.
On review of his peripheral smear, there was marked macrocytosis with anisocytosis and polychromatophilia. There was an occasional spherocyte and 36% nucleated red cells, some of which were dysplastic. He had rare basophils, myeloblasts and myelocytes. Platelets were markedly reduced but without abnormal forms. A bone marrow aspirate was hypercellular (95%) with reduced megakaryocytes. There was marked erythroid hyperplasia with mild dysplasia but without significant immaturity in the erythroid precursors. The myeloid/ erythroid (M/E) ratio was 0.2:1. Erythroid precursors constituted 85% of cells. There was impaired maturation in the myeloid series but only 1.5% myeloblasts. An iron stain showed 7% of erythroid precursors to be ringed sideroblasts.
Figure 1
Bone marrow aspirate and biopsy at the time of diagnosis.
